Phibro Animal Health Corporation (PAHC) Income Statement Analysis

See more : Biomerica, Inc. (BMRA) Income Statement Analysis – Financial Results

Complete financial analysis of Phibro Animal Health Corporation (PAHC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Phibro Animal Health Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.

You may be interested

Altius Renewable Royalties Corp. (ATRWF) Income Statement Analysis – Financial Results
Yungjin Pharm. Co., Ltd. (003520.KS) Income Statement Analysis – Financial Results
Welspun Corp Limited (WELCORP.BO) Income Statement Analysis – Financial Results
Baoshan Iron & Steel Co., Ltd. (600019.SS) Income Statement Analysis – Financial Results
N R Agarwal Industries Limited (NRAIL.NS) Income Statement Analysis – Financial Results

Phibro Animal Health Corporation (PAHC)

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: https://www.pahc.com

About Phibro Animal Health Corporation

Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Revenue	1.02B	977.89M	942.30M	833.40M	800.40M	828.00M	820.00M	764.30M	751.50M	748.59M	691.90M	653.15M	654.10M	618.33M	594.20M	537.10M	511.40M	453.00M	398.40M	364.40M	354.40M	337.80M	328.70M	319.70M	323.00M
Cost of Revenue	704.59M	679.65M	656.90M	562.00M	543.50M	563.40M	553.10M	516.00M	512.50M	512.22M	484.10M	474.19M	489.96M	471.67M	439.50M	407.50M	389.70M	341.80M	307.30M	293.10M	265.20M	248.60M	247.40M	250.30M	249.60M
Gross Profit	313.09M	298.24M	285.40M	271.40M	256.90M	264.60M	266.90M	248.30M	239.00M	236.37M	207.80M	178.96M	164.14M	146.67M	154.70M	129.60M	121.70M	111.20M	91.10M	71.30M	89.20M	89.20M	81.30M	69.40M	73.40M
Gross Profit Ratio	30.77%	30.50%	30.29%	32.57%	32.10%	31.96%	32.55%	32.49%	31.80%	31.58%	30.03%	27.40%	25.09%	23.72%	26.04%	24.13%	23.80%	24.55%	22.87%	19.57%	25.17%	26.41%	24.73%	21.71%	22.72%
Research & Development	29.19M	24.40M	20.83M	17.76M	13.74M	12.08M	10.00M	9.44M	11.03M	9.51M	8.21M	6.64M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	101.90M	84.60M	81.30M	76.20M	68.10M	66.90M	63.40M	63.30M	70.60M	63.90M	59.30M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	220.88M	226.39M	206.40M	196.50M	187.70M	181.40M	168.00M	150.30M	153.30M	148.70M	144.00M	122.23M	114.81M	105.43M	101.90M	84.60M	81.30M	76.20M	68.10M	66.90M	63.40M	63.30M	70.60M	63.90M	59.30M
Other Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-151.00K	400.00K	-593.00K	0.00	3.60M	11.10M	14.00M	0.00	0.00	-17.90M	0.00	0.00	0.00	-1.50M
Operating Expenses	260.30M	226.39M	206.40M	196.50M	187.70M	181.40M	168.00M	150.30M	153.30M	148.70M	144.00M	122.23M	114.81M	105.43M	101.90M	88.20M	92.40M	90.20M	68.10M	66.90M	45.50M	63.30M	70.60M	63.90M	57.80M
Cost & Expenses	964.36M	906.04M	863.30M	758.50M	731.20M	744.80M	721.10M	666.30M	665.80M	660.92M	628.10M	596.42M	604.78M	577.10M	541.40M	495.70M	482.10M	432.00M	375.40M	360.00M	310.70M	311.90M	318.00M	314.20M	307.40M
Interest Income	4.47M	3.36M	816.00K	838.00K	1.76M	1.90M	1.69M	1.97M	256.00K	249.00K	119.00K	142.00K	281.00K	307.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	21.97M	17.95M	11.90M	12.90M	12.90M	11.80M	11.90M	14.90M	16.60M	14.55M	33.00M	35.77M	35.70M	34.60M	-33.10M	-43.40M	-26.90M	-27.30M	-32.60M	-26.90M	-20.60M	-17.40M	-17.70M	-17.70M	-14.20M
Depreciation & Amortization	36.18M	34.01M	32.71M	31.89M	32.34M	27.56M	26.94M	26.00M	23.45M	21.60M	21.45M	19.02M	17.53M	16.70M	-40.00M	-89.70M	-51.40M	10.72M	13.99M	18.11M	10.66M	10.99M	12.36M	10.41M	11.87M
EBITDA	84.61M	116.63M	114.82M	105.50M	102.16M	112.75M	128.62M	123.42M	117.06M	114.92M	60.84M	72.64M	66.34M	43.40M	12.80M	-48.30M	-22.10M	-22.88M	-26.51M	-28.79M	10.76M	-14.21M	-42.34M	-22.59M	11.67M
EBITDA Ratio	8.31%	11.09%	8.38%	8.99%	8.65%	10.07%	12.06%	12.81%	11.42%	14.63%	9.24%	11.60%	10.32%	9.32%	2.15%	-8.99%	-4.32%	-5.05%	-6.65%	-7.90%	3.04%	-4.21%	-12.88%	-7.07%	3.61%
Operating Income	53.32M	71.85M	46.30M	43.02M	36.86M	73.30M	98.90M	97.90M	85.70M	87.67M	63.80M	56.73M	49.33M	41.24M	52.80M	41.40M	29.30M	21.10M	23.00M	4.40M	43.70M	25.90M	10.60M	5.40M	15.70M
Operating Income Ratio	5.24%	7.35%	4.91%	5.16%	4.61%	8.85%	12.06%	12.81%	11.40%	11.71%	9.22%	8.69%	7.54%	6.67%	8.89%	7.71%	5.73%	4.66%	5.77%	1.21%	12.33%	7.67%	3.22%	1.69%	4.86%
Total Other Income/Expenses	-42.40M	-17.78M	-6.66M	-8.40M	-13.68M	-11.72M	-10.86M	-17.39M	-19.44M	-8.91M	-57.49M	-38.88M	-36.21M	-49.13M	-33.20M	-43.50M	-27.40M	-27.40M	-30.90M	-25.80M	-19.80M	-18.90M	-21.00M	-17.10M	-1.70M
Income Before Tax	10.92M	54.07M	72.30M	66.50M	55.50M	71.50M	88.10M	80.50M	76.80M	78.76M	6.30M	17.85M	13.11M	-7.89M	19.60M	-2.10M	1.90M	-6.30M	-7.90M	-21.40M	23.90M	7.00M	-10.40M	-11.70M	14.00M
Income Before Tax Ratio	1.07%	5.53%	7.67%	7.98%	6.93%	8.64%	10.74%	10.53%	10.22%	10.52%	0.91%	2.73%	2.00%	-1.28%	3.30%	-0.39%	0.37%	-1.39%	-1.98%	-5.87%	6.74%	2.07%	-3.16%	-3.66%	4.33%
Income Tax Expense	8.50M	21.47M	23.20M	12.10M	22.00M	16.80M	23.20M	15.90M	-6.00M	18.48M	9.40M	-7.04M	6.14M	5.03M	3.80M	3.40M	2.60M	400.00K	5.20M	2.10M	7.80M	9.80M	14.80M	-400.00K	3.90M
Net Income	2.42M	32.61M	49.18M	54.39M	33.55M	54.70M	64.90M	64.60M	82.70M	60.28M	-3.10M	24.89M	6.98M	-12.92M	42.10M	-8.30M	2.20M	-6.70M	-13.10M	-22.10M	12.90M	-17.60M	-51.80M	-14.90M	10.10M
Net Income Ratio	0.24%	3.33%	5.22%	6.53%	4.19%	6.61%	7.91%	8.45%	11.00%	8.05%	-0.45%	3.81%	1.07%	-2.09%	7.09%	-1.55%	0.43%	-1.48%	-3.29%	-6.06%	3.64%	-5.21%	-15.76%	-4.66%	3.13%
EPS	0.06	0.81	1.21	1.34	0.83	1.35	1.61	1.63	2.11	1.55	-0.10	0.82	0.23	-0.42	1.09	-0.21	0.06	-0.17	-0.22	-0.37	0.22	-0.29	-0.86	-0.25	0.17
EPS Diluted	0.06	0.81	1.21	1.34	0.83	1.35	1.61	1.61	2.07	1.51	-0.10	0.82	0.23	-0.42	1.09	-0.21	0.06	-0.17	-0.22	-0.37	0.22	-0.29	-0.86	-0.25	0.17
Weighted Avg Shares Out	40.50M	40.50M	40.50M	40.47M	40.45M	40.41M	40.20M	39.50M	39.30M	38.97M	31.27M	30.46M	30.46M	30.46M	38.80M	38.80M	38.80M	38.80M	60.00M	60.00M	60.00M	60.00M	60.00M	60.00M	60.00M
Weighted Avg Shares Out (Dil)	40.52M	40.50M	40.50M	40.50M	40.50M	40.52M	40.40M	40.00M	40.00M	39.82M	32.20M	30.46M	30.53M	30.46M	38.80M	38.80M	38.80M	38.80M	60.00M	60.00M	60.00M	60.00M	60.00M	60.00M	60.00M

Are You Looking for a Top Momentum Pick? Why Phibro Animal Health (PAHC) is a Great Choice

September 6, 2024zacks.com

Does Phibro Animal Health (PAHC) have what it takes to be a top stock pick for momentum investors? Let's find out.

PAHC vs. ABT: Which Stock Should Value Investors Buy Now?

September 2, 2024zacks.com

Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?

Here's Why Phibro Animal Health (PAHC) is a Strong Momentum Stock

September 2, 2024zacks.com

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Phibro (PAHC) International Revenue Performance Explored

September 2, 2024zacks.com

Examine the evolution of Phibro's (PAHC) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Phibro Animal Health Corporation (PAHC) Q4 2024 Earnings Call Transcript

August 29, 2024seekingalpha.com

Phibro Animal Health Corporation (NASDAQ:PAHC ) Q4 2024 Earnings Call Transcript August 29, 2024 9:00 AM ET Company Participants Glenn David - CFO Jack Bendheim - Chairman, President, and CEO Daniel Bendheim - Director and EVP of Corporate Strategy Conference...

Phibro Animal Health Corporation to Participate at Morgan Stanley Annual Global Healthcare Conference

August 29, 2024businesswire.com

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference. Chief Financial Officer, Glenn David along with Chief Operating Officer, Larry Miller will address financial analysts and investors on...